Document is current
Any future updates will be listed below
-
Authors
Pizzuto, Malvina https://orcid.org/0000-0001-6330-6937
Monteleone, Mercedes https://orcid.org/0000-0003-0777-3965
Burgener, Sabrina Sofia https://orcid.org/0000-0002-9332-7998
Began, Jakub
Kurera, Melan
Chia, Jing Rong
Frampton, Emmanuelle
Crawford, Joanna https://orcid.org/0000-0003-0786-6889
Oliveira, Monalisa https://orcid.org/0009-0000-0363-4031
Kenney, Kirsten M
Coombs, Jared R https://orcid.org/0000-0002-1703-1247
Yamamoto, Masahiro https://orcid.org/0000-0002-6821-2785
Man, Si Ming https://orcid.org/0000-0002-5079-2857
Broz, Petr https://orcid.org/0000-0002-2334-7790
Pelegrin, Pablo https://orcid.org/0000-0002-9688-1804
Schroder, Kate https://orcid.org/0000-0001-9261-3805
-
Funding
Funding for this research was provided by:
Spanish Ministry of Science and Innovation (PID2023-147531OB-I00, CNS2022-135105)
Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033)
Ministerio de Ciencia e Innovación (PID2020-116709RB-I00)
Ministerio de Ciencia e Innovación (FJC2018-036217-I)
fundacion séneca (21897/PI/22,20859/PI/18,21081/PDC/19 and 0003/COVI/20)
Instituto Salud Carlos III (AC22/00009)
European Research Council (ERC-2013-CoG 614578 and ERC-2019-PoC 899636)
Australian Research Council (DP190102285)
National Health and Medical Research Council of Australia (Synergy Grant 2009677)
National Health and Medical Research Council of Australia (Fellowship 2009075)
Barth Syndrome Foundation
Fond National de la Recherche Scientifique (CR 32774874)
The John Curtin School of Medical Research
CSL Centenary Fellowship
Swiss National Science Foundation (P2BEP3)
Novartis Foundation for Biomedical-Research (21C133)
- License Information
-
More Information
Article History
Received: 8 January 2025
Revised: 12 June 2025
Accepted: 16 June 2025
First Online: 16 July 2025
Disclosure and competing interests statement
: As co-founder of Viva in vitro diagnostics, PP declares that the research presented herein was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. KS is a co-inventor on patent applications for NLRP3 inhibitors licensed to Inflazome Ltd., a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease. KS served on the Scientific Advisory Board of Inflazome in 2016–2017, and serves as a consultant to Quench Bio, USA, and Novartis, Switzerland. The authors declare no additional competing interests.
